Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Pfizer Inc., solvency ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


Over the observed period, the company’s solvency ratios demonstrate a generally increasing trend in leverage, particularly noticeable in the latter half of the analyzed timeframe. While initial values suggest a relatively conservative capital structure, subsequent quarters reveal a gradual increase in reliance on debt financing. This analysis details the observed trends in debt to equity, debt to capital, debt to assets, and financial leverage ratios.

Debt to Equity Ratio
The debt to equity ratio began at 0.44 and generally decreased through December 31, 2022, reaching a low of 0.37. However, a significant increase is observed beginning with the April 2, 2023, period, rising to 0.66 and peaking at 0.81 by December 31, 2023. The ratio subsequently decreased to 0.69 by March 30, 2025, but remains substantially higher than the initial values. This indicates a growing proportion of debt relative to equity financing.
Debt to Capital Ratio
Similar to the debt to equity ratio, the debt to capital ratio exhibited a slight decline from 0.31 to 0.27 during the first four quarters. A marked increase then commenced, reaching 0.45 by December 31, 2023. The ratio stabilized somewhat in subsequent periods, fluctuating between 0.41 and 0.44, before increasing to 0.43 by December 31, 2025. This pattern mirrors the trend in the debt to equity ratio, suggesting a consistent shift towards debt financing within the company’s capital structure.
Debt to Assets Ratio
The debt to assets ratio followed a comparable trajectory, decreasing from 0.20 to 0.18 through December 31, 2022. A subsequent rise began in April 2023, reaching 0.32 by December 31, 2023, and remaining relatively stable between 0.30 and 0.32 for the remainder of the period, concluding at 0.31. This indicates an increasing proportion of assets financed by debt.
Financial Leverage Ratio
The financial leverage ratio demonstrated a similar pattern of initial decline followed by a substantial increase. Starting at 2.23, it decreased to 1.94 by April 2, 2023. However, it then increased significantly, peaking at 2.54 by December 31, 2023. The ratio moderated slightly in subsequent periods, fluctuating around 2.30-2.40, and concluded at 2.41. This suggests a growing reliance on debt to amplify returns on equity, and a corresponding increase in financial risk.

In summary, the observed trends indicate a notable shift towards increased financial leverage over the analyzed period. While the initial quarters suggest a conservative approach to debt, the company has demonstrably increased its reliance on debt financing in subsequent periods. This trend is consistent across all four solvency ratios examined.


Debt Ratios


Debt to Equity

Pfizer Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total Pfizer Inc. shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q4 2025 Calculation
Debt to equity = Total debt ÷ Total Pfizer Inc. shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The debt-to-equity ratio for the analyzed period demonstrates a fluctuating pattern, generally trending upwards with a notable increase in the latter half of the observed timeframe. Initially, the ratio exhibited relative stability, followed by a period of significant change, and then a leveling off before a final increase.

Initial Stability (Apr 3, 2022 – Dec 31, 2022)
The debt-to-equity ratio began at 0.44 and gradually increased to 0.46, then decreased to 0.37 by the end of 2022. This suggests a relatively balanced financial structure during this period, with moderate leverage. The fluctuations within this timeframe were not substantial.
Significant Increase (Apr 2, 2023 – Dec 31, 2023)
A substantial increase in the ratio is observed starting in April 2023, reaching 0.66, 0.66, and peaking at 0.81 by December 2023. This indicates a considerable rise in the proportion of debt financing relative to equity. The increase suggests the entity may have taken on additional debt or experienced a decrease in shareholders’ equity, or a combination of both.
Plateau and Subsequent Increase (Mar 31, 2024 – Dec 31, 2025)
Following the peak in December 2023, the ratio experienced a slight decline to 0.75, then fluctuated between 0.66 and 0.79 over the subsequent quarters. However, the ratio concludes the period at 0.75, indicating a renewed upward trend. This suggests that while the rapid increase in leverage was temporarily contained, debt levels are again rising relative to equity.

Overall, the trend suggests a shift towards increased financial leverage over the analyzed period. While the initial period demonstrated a more conservative capital structure, the later quarters reveal a growing reliance on debt financing. The fluctuations observed throughout the period warrant further investigation to understand the underlying drivers of these changes.


Debt to Capital

Pfizer Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt
Long-term debt, excluding current portion
Total debt
Total Pfizer Inc. shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q4 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The debt to capital ratio exhibits a generally increasing trend over the observed period, punctuated by periods of relative stability. Initially, the ratio fluctuates within a narrow range before demonstrating a more pronounced upward movement.

Initial Period (Apr 3, 2022 – Dec 31, 2022)
The debt to capital ratio begins at 0.31 and experiences a slight increase to 0.32, followed by declines to 0.28 and 0.27. This suggests a relatively stable capital structure with minor adjustments in the proportion of debt financing during this timeframe. Total debt decreased from US$36,301 million to US$35,829 million, while total capital increased from US$118,725 million to US$131,490 million.
Significant Increase (Apr 2, 2023 – Dec 31, 2023)
A substantial increase in the ratio is observed, rising from 0.26 to 0.45. This is primarily driven by a significant increase in total debt, from US$35,892 million to US$71,888 million, while total capital also increased, but at a slower pace, from US$136,862 million to US$160,902 million. This indicates a notable shift towards greater reliance on debt financing.
Stabilization and Subsequent Fluctuations (Mar 31, 2024 – Dec 31, 2025)
Following the peak of 0.45, the ratio experiences a slight decline to 0.41, then fluctuates between 0.40 and 0.44 over the subsequent nine periods. Total debt generally decreases from US$69,539 million to US$64,795 million, but total capital also experiences a similar downward trend, from US$161,821 million to US$151,271 million. This suggests a period of managing debt levels alongside overall capital adjustments. The ratio concludes the period at 0.43, representing an overall increase from the initial value of 0.31.

In summary, the observed trend indicates an increasing reliance on debt financing over the analyzed period, particularly pronounced between April 2023 and December 2023. While the ratio stabilizes in the later periods, it remains elevated compared to the initial values, suggesting a sustained change in the company’s capital structure.


Debt to Assets

Pfizer Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q4 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The debt-to-assets ratio exhibits a generally increasing trend over the observed period, punctuated by periods of relative stability. Initially, the ratio fluctuates between 0.19 and 0.21 from April 2022 to December 2022, indicating a consistent level of financial leverage. A significant increase is then observed, with the ratio rising to 0.30 by July 2023 and remaining at that level through September 2025. A slight increase to 0.31 is noted in December 2023 and again in December 2025.

Initial Period (Apr 2022 - Dec 2022)
The debt-to-assets ratio remained relatively stable, ranging from 0.18 to 0.21. This suggests a consistent reliance on debt financing relative to the company’s asset base during this timeframe. The slight fluctuations within this range do not indicate a substantial shift in the company’s financial structure.
Significant Increase (Jul 2023 - Sep 2025)
A notable increase in the ratio is apparent beginning in July 2023, reaching 0.30 and persisting through September 2025. This indicates a greater proportion of assets are financed by debt. The increase suggests a potential shift in financing strategy, increased borrowing, or a decrease in asset value, or a combination of these factors. The consistency at 0.30 suggests a stabilization of this increased leverage.
Recent Fluctuations (Dec 2023 & Dec 2025)
Minor increases to 0.31 are observed in December 2023 and December 2025. These slight increases, while not substantial, warrant monitoring to determine if they represent the beginning of a new upward trend or are simply temporary variations.

Overall, the trend suggests a growing reliance on debt financing relative to assets. While the ratio remains below 0.32 throughout the period, the sustained increase from 0.19 to 0.31 indicates a change in the company’s capital structure that merits further investigation to understand the underlying drivers and potential implications for financial risk.


Financial Leverage

Pfizer Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Total assets
Total Pfizer Inc. shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q4 2025 Calculation
Financial leverage = Total assets ÷ Total Pfizer Inc. shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial leverage ratio for the analyzed period demonstrates fluctuations, generally trending upwards with some periods of decline. Initial values indicate a leverage ratio around 2.2, which subsequently increased to approximately 2.5 before settling back towards 2.4 by the end of the observed timeframe.

Overall Trend
From April 2022 through June 2025, the financial leverage ratio exhibits a generally increasing trend. While there are quarterly variations, the ratio moves from 2.23 to 2.41. This suggests a growing reliance on debt financing relative to equity.
Initial Period (Apr 2022 – Dec 2022)
The ratio remained relatively stable between April 2022 and December 2022, fluctuating between 2.10 and 2.24. This indicates a consistent, moderate level of financial leverage during this period. A slight decrease is observed from July to October 2022, followed by a minor increase by the end of the year.
Increase and Subsequent Stabilization (Apr 2023 – Jun 2024)
A noticeable increase in the ratio occurred between April 2023 and October 2023, rising from 1.94 to 2.22. The ratio peaked at 2.54 in December 2023 before decreasing slightly to 2.47 in June 2024. This period represents the highest levels of financial leverage observed throughout the analyzed timeframe.
Recent Period (Sep 2024 – Jun 2025)
The most recent six quarters show a slight downward trend, with the ratio decreasing from 2.38 in September 2024 to 2.32 in June 2025. However, this decrease is relatively small, and the ratio remains elevated compared to earlier periods. The final reported value is 2.41.

The observed increases in the financial leverage ratio suggest that the entity has been increasing its use of debt to finance its assets. While not necessarily indicative of financial distress, continued monitoring of this ratio is warranted to ensure that debt levels remain manageable and do not pose undue risk.